Lycia Therapeutics Inc
LYCAHealthcare·Biotechnology·USA·Small·NASD·Nov 12 • 1:57 PM ET
Price
LYCA against its price10.8% under the 52-week high of 36.49 on 23 Oct 2026. 52-week low 22.19 on 23 Oct 2026. Last 15 sessions, 64.5% high to low. This session is unfinished.
Volume 0.96× normal · the line is the 50-bar volume average
Setup
CANSLIM 1 of 6 — fails: 52-Week High/Low: 0-10% below High; Institutional Ownership: Over 50% — not on the tape: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); Performance: Year +50%
VCP 2 of 6 — fails: 52-Week High/Low: 0-10% below High; Average True Range: Under 2 — not on the tape: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200
Minervini 0 of 4 — fails: 52-Week High/Low: 0-10% below High — not on the tape: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; Performance: Year +50%
Zanger 2 of 5 — fails: 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5 — not on the tape: 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: Average Volume: Over 500K; 52-Week High/Low: 0-10% below High — not on the tape: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2 — not on the tape: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 0 of 4 — not on the tape: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 0 of 5 — not on the tape: Return on Equity: Over +15%; Net Profit Margin: High (>20%); Debt/Equity: Low (<0.1); P/E: Under 25; Current Ratio: Over 1
Value 0 of 4 — not on the tape: P/E: Under 15; P/B: Under 2; Return on Equity: Over +15%; Debt/Equity: Low (<0.1)
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 0 of 4 — fails: Average Volume: Over 500K — not on the tape: Float: Under 100M; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Ownership: Over 30% — not on the tape: 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Average Volume: Over 500K — not on the tape: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
LYCALycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.
| IPO | Oct 23, 2026 |
|---|---|
| ATR, 14d | 3.40 |
| Rel volume | 0.96 |
| Inst own | 12.34% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $1.88B |
| Enterprise Value | - |
| Income | - |
| Sales | - |
| Book / share | - |
| Cash / share | - |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | - |
| IPO | Oct 23, 2026 |
Ratios
Earnings
Ownership
| Insiders own | - |
|---|---|
| Insider trades | - |
| Institutions own | 12.34% |
| Institution trades | 16.49% |
| Return on assets | - |
| Return on equity | - |
| Return on capital | - |
| Gross Margin | - |
| Operating margin | - |
| Profit Margin | - |
| 20-day average | 12.79% |
| 50-day average | 12.79% |
| 200-day average | 12.79% |
Technical
| Shares out | 55.03M |
|---|---|
| Shares floating | - |
| Short / float | - |
| Short ratio | 0.65 |
| Short interest | 0.30M |
| 52-week high | 36.49 -10.8% |
| 52-week low | 22.19 +46.7% |
| Volatility | 6.70% - |
| Average range | 3.40 |
| Strength index | 58.14 |
| Market sensitivity | - |
| Relative volume | 0.96 |
| Avg Volume | 469.26K |
| Volume | 315,889 |
Performance
| Perf Week | 13.00% |
|---|---|
| Perf Month | - |
| Perf Quarter | - |
| Perf Half Y | - |
| Perf YTD | 13.99% |
| Perf Year | - |
| Perf 3Y | - |
| Perf 5Y | - |
| Perf 10Y | - |
| Recommendation | - |
| Target Price | - |
| Prev Close | 31.44 |
| Price | 32.54 |
| Change % | 3.51% |
Insider trading
7 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Par | 10% Owner | Nov 02 '26 | Buy | 26.95 | 8,305 | 223,820 | 6,858,542 | Nov 04 05:12 PM |
| Venrock Healthcare Capital Par | 10% Owner | Oct 28 '26 | Buy | 25.45 | 15,000 | 381,728 | 6,840,233 | Oct 30 07:25 PM |
| Venrock Healthcare Capital Par | 10% Owner | Oct 30 '26 | Buy | 26.28 | 9,004 | 236,653 | 6,850,237 | Oct 30 07:25 PM |
| Venrock Healthcare Capital Par | 10% Owner | Oct 29 '26 | Buy | 26.33 | 1,000 | 26,330 | 6,841,233 | Oct 30 07:25 PM |
| Venrock Healthcare Capital Par | 10% Owner | Oct 26 '26 | Buy | 18.04 | 1,952,705 | 35,222,791 | 6,785,437 | Oct 27 06:38 PM |
| Venrock Healthcare Capital Par | 10% Owner | Oct 23 '26 | Buy | 25.91 | 52,939 | 1,371,676 | 52,939 | Oct 27 06:38 PM |
| Venrock Healthcare Capital Par | 10% Owner | Oct 27 '26 | Buy | 26.62 | 39,796 | 1,059,396 | 6,825,233 | Oct 27 06:38 PM |
Held by
AUMQuarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| No quarterly earnings. | |||||||
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| No annual earnings. | |||||
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| No estimate revisions. | ||||||||
Estimate history
| EPS, annual |
|---|
| Period |
| EPS, quarterly |
| Period |
| Sales, annual |
| Period |
| Sales, quarterly |
| Period |
| Shares, annual |
| Period |
| Shares, quarterly |
| Period |
Income statement, annual
No statement data.
Income statement, quarterly
No statement data.
Balance sheet, annual
No statement data.
Cash flow, annual
No statement data.
Balance sheet, quarterly
No statement data.
Cash flow, quarterly
No statement data.
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | - | 0.3M | - | 747.92K |
Option chain
expiry 2026-11-12| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-04 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-02 | SEC |
| 2026-10-30 | SCHEDULE 13G | SEC | ||
| 2026-10-30 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-28 | SEC |
| 2026-10-28 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-26 | SEC |
| 2026-10-27 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-23 | SEC |
| 2026-10-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-11 | SEC |
| 2026-10-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-11 | SEC |
| 2026-10-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-11 | SEC |
| 2026-10-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-11 | SEC |
| 2026-10-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-11 | SEC |
| 2026-10-26 | 8-K | Current report | 2026-10-26 | SEC |
| 2026-10-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-11 | SEC |
| 2026-10-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-11 | SEC |
| 2026-10-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-11 | SEC |
| 2026-10-23 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans | SEC | |
| 2026-10-23 | 424B4 | SEC | ||
| 2026-10-22 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-10-22 | 3 | Initial statement of beneficial ownership of securities | 2026-10-22 | SEC |
| 2026-10-22 | 3 | Initial statement of beneficial ownership of securities | 2026-10-22 | SEC |
| 2026-10-22 | 3 | Initial statement of beneficial ownership of securities | 2026-10-22 | SEC |
| 2026-10-22 | 3 | Initial statement of beneficial ownership of securities | 2026-10-22 | SEC |
| 2026-10-22 | 3 | Initial statement of beneficial ownership of securities | 2026-10-22 | SEC |
| 2026-10-22 | 3 | Initial statement of beneficial ownership of securities | 2026-10-22 | SEC |
| 2026-10-22 | S-1MEF | A new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S-1 | SEC | |
| 2026-10-22 | 3 | Initial statement of beneficial ownership of securities | 2026-10-22 | SEC |
| 2026-10-22 | 3 | Initial statement of beneficial ownership of securities | 2026-10-22 | SEC |
| 2026-10-22 | CERT | SEC | ||
| 2026-10-22 | 3 | Initial statement of beneficial ownership of securities | 2026-10-22 | SEC |
| 2026-10-22 | 3 | Initial statement of beneficial ownership of securities | 2026-10-22 | SEC |
| 2026-10-22 | 3 | Initial statement of beneficial ownership of securities | 2026-10-22 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 223.82K | 1 | 0 | 0 |
| 2026-10 | 38.30M | 6 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| - | |
Funds
| Fund | % owned |
|---|---|
| - | |
OakChart. LYCA. Cached 15 minutes. Terms
Some panels did not load: ratings, news.